Complaince Certificate under Reg 74(5) of SEBI(DP) Regulation for the Q ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has submitted a quarterly compliance certificate under SEBI Regulation 74(5) to BSE, CDSL, and NSDL. The certificate, issued by MUFG Intime India Pvt. Ltd. (the company's Registrar and Share Transfer Agent), dated 4th July 2025, confirms that all securities received from depository participants for demat during the quarter ended 30th June 2025 were duly processed. It further confirms that physical share certificates received for dematerialisation were mutilated and cancelled, and the depository's name was substituted in the register of members within the prescribed timelines. The filing was made by the Company Secretary, Pratika Mhambray, on 7th July 2025.
This is a routine quarterly regulatory compliance filing with no material impact on the company's business, financials, or stock price. It simply confirms proper handling of share dematerialisation requests during the quarter.